Perhaps ….one can speculate on this weeks press release ??
Positron Retains Healthcare Advisor I-Square Ventures to Implement Strategy and Expand Market Share
Niagara Falls, NY – July 15, 2021 (GLOBE NEWSWIRE) -- Positron Corporation (“Positron” or the “Company”) (OTC: POSC) is pleased to announce today that it has retained the services of I- Square Ventures (“I-Square”) to refine the Company’s value proposition and further advance the go to market strategy within the nuclear medicine arena.
I-Square is a boutique growth strategy consulting firm that has developed growth strategies, execution processes, and technology solutions that have delivered billions of dollars in free cash flow growth for large public companies and small private companies in the Healthcare, Insurance and Technology industries.
Adel Abdullah, President of Positron stated: "Positron is at a significant inflection point and in an ideal position to capitalize on a very positive environment and outlook for PET technology. With many expected milestones for Positron, we believed bringing on board the expertise of a seasoned healthcare industry team in I-Square and its Managing Partner Dr. Chiranjeev “CJ” Bordoloi was important to further solidify our focus on strategy, sales and market penetration moving forward. Expanding our team strategically, and deepening our reach within the nuclear imaging industry, should greatly advance and accelerate our progress. We are very pleased to welcome a group of growth experts led by Dr. Bordoloi to our team at this exciting time for Positron.”
Dr. Chiranjeev “CJ” Bordoloi, Managing Partner or of I-Square Ventures, commented: “In our detailed and thorough due diligence cycle of analyzing players in the nuclear imaging industry, along with input from large healthcare institutional clients, we believe that Positron is uniquely positioned to grow market share and benefit as the industry experiences the advantages of migrating from SPECT to PET systems. While the superiority of PET technology over SPECT has long been known, pricing has previously been the main issue slowing this adoption. Positron has leveraged technology innovation to design efficiencies and reduce costs that make PET pricing comparable to SPECT, while at the same time providing superior diagnostic accuracy,